AIM ImmunoTech is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders

AIM ImmunoTech is engaged in the clinical development of new drug entities for the treatment of seriously debilitating disorders

AIM ImmunoTech Blog

Latest From

AIM ImmunoTech

  • Hemispherx News 05

AIM ImmunoTech Announces the National Cancer Institute’s Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers

April 6th, 2020|

AIM ImmunoTech Announces the National Cancer Institute's Award of $14.54M to Study Ampligen as Part of Five Roswell Park-led Chemokine Modulation Clinical Trials in Melanoma, Colorectal and Ovarian Cancers We recently announced [...]

  • Hemispherx News 05

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic

March 26th, 2020|

AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic We recently announced the AIM ImmunoTech team is working [...]

Want More Info?

Click below for all our contact information

Let’s Talk